Johnson & Johnson

NYSE:JNJ  
181.06
+1.60 (+0.89%)
4:17:23 PM EDT: $181.25 +0.19 (+0.11%)
Products

Janssen Says FDA Approved A Label Update For CABENUVA

Published: 03/24/2022 18:59 GMT
Johnson & Johnson (JNJ) - :u.s. FDA Approves Streamlined Process for Initiating Hiv Therapy With Cabenuva (cabotegravir and Rilpivirine), the First and Only Complete Long-acting Injectable Hiv Treatment.
Janssen - FDA Approved a Label Update for Cabenuva.
Janssen - Adults Living With Hiv Now Have an Option to Start Injectable Regimen Without the Need for an Oral Lead-in Period First.